The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Generali, Daniele, Sobhani, Navid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797650/
https://www.ncbi.nlm.nih.gov/pubmed/35117071
http://dx.doi.org/10.21037/tcr.2018.10.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797650/
https://www.ncbi.nlm.nih.gov/pubmed/35117071
http://dx.doi.org/10.21037/tcr.2018.10.17

Ejemplares similares